TapImmune Announces Licensing Agreement with Mayo Clinic to Commercialize a Folate Receptor Alpha Vaccine for Multiple Cancer Indications
July 28th, 2015 | Posted In: Newsletter Articles, Research - Closer to the FinishSeattle WA, July 27, 2015 – TapImmune, Inc. (OTCQB: TPIV), a clinical stage cancer immunotherapy company is pleased to announce that the Company has exercised its option agreement with Mayo Clinic. TapImmune has signed a worldwide exclusive license agreement to commercialize a proprietary folate receptor alpha vaccine technology for all cancer indications. This technology, developed in the laboratory of Keith Knutson, Ph.D., at Mayo, has successfully completed Phase I clinical trials in ovarian and triple-negative breast cancer.
Read Complete Press Release (PDF)
Register Now Button
Donate Now Button
Stay Posted
Locals Rule
YesWay
Team Donna
Donna partners
The Donna Foundation
Jeff Galloway
Mayo Clinic
Learn More
Leave a Reply
Be the First to Comment!